Phenotypes Associated with This Genotype

Genotype
MGI:5464998

• Allelic Composition: Meis1^tm2Ngc/Meis1^tm2Ngc; Tg(Tal1-cre/ERT)42-056Jrg/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * C57BL/6J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

abnormal bone marrow cell morphology/development ( J:192126 )

• tamoxifen-treated mice exhibit reduction in granulocyte-monocyte progenitor (GMPs) and common myeloid progenitor (CMPs) cells and mild reduction in the total number of megakaryocyte/erythroid progenitor cells (MEP) compared with control mice

• however, tamoxifen-treated mice exhibit normal percentage of differentiated myeloid progenitor cells and erythroid progenitor cells and BFU-E and total number of colonies are rescued by re-expression of Hif1a

decreased common myeloid progenitor cell number ( J:192126 )

• tamoxifen-treated mice exhibit reduced common myeloid progenitors and primitive myeloid progenitors compared with control mice

increased hematopoietic stem cell number ( J:192126 )

• increased frequency in tamoxifen-treated mice

abnormal hematopoietic stem cell physiology ( J:192126 )

• long-term hematopoietic stem cells are less quiescent, prone to proliferation and more apoptotic in tamoxifen-treated mice than in control mice

cellular

oxidative stress ( J:192126 )

• increased reactive oxygen species in the long-term hematopoietic stem cells of tamoxifen-treated mice

• however, treatment with N-acetyl-L-cysteine (NAC) restores reactive oxygen species